Coronary heart disease remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.
For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops.
What makes CHD numbers particularly troubling is that so much of this is preventable. Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level. These tests aim to detect CHD earlier and more accurately than traditional risk calculators, potentially saving lives by identifying at-risk individuals who would otherwise be overlooked.
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. Forward-looking statements in this article are subject to risks and uncertainties as described in the company's SEC filings. Please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
